Serum sickness following treatment with rituximab

被引：3

作者：

Todd, Derrick J. ^{[1
]}

Helfgott, Simon M. ^{[1
]}

机构：

[1] Brigham & Womens Hosp, Ctr Arthritis, Dept Rheumatol Immunol & Allergy, Boston, MA 02115 USA

来源：

JOURNAL OF RHEUMATOLOGY | 2007年 / 34卷 / 02期

关键词：

serum sickness; rituximab; arthritis; case report; adverse drug reaction;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Serum sickness, an illness characterized by fever, rash, and arthralgias, can occur in patients who receive chimeric monoclonal antibody therapy. Rituximab, a B cell-depleting chimeric anti-CD20 monoclonal antibody, has been used with increasing frequency in the treatment of rheumatologic illnesses such as rheumatoid arthritis and systemic lupus erythematosus. Serum sickness has only rarely been reported following rituximab therapy. All prior reported cases have been in patients with autoimmune conditions. We describe a case of serum sickness in a patient treated with rituximab for mantle cell lymphoma. We also review the literature of rituximab-induced serum sickness.

引用

页码：430 / 433

页数：4

共 18 条

[1] Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura [J].

Bennett, CM ;

Rogers, ZR ;

Kinnamon, DD ;

Bussel, JB ;

Mahoney, DH ;

Abshire, TC ;

Sawaf, H ;

Moore, TB ;

Loh, ML ;

Glader, BE ;

McCarthy, MC ;

Mueller, BU ;

Olson, TA ;

Lorenzana, AN ;

Mentzer, WC ;

Buchanan, GR ;

Feldman, HA ;

Neufeld, EJ .

BLOOD, 2006, 107 (07) :2639-2642

[2] Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia [J].

Catuogno, M ;

Rezai, S ;

Priori, R ;

Magrini, L ;

Valesini, G .

RHEUMATOLOGY, 2005, 44 (03) :406-406

[3]

D'Arcy CA, 2001, ARTHRITIS RHEUM, V44, P1717, DOI 10.1002/1529-0131(200107)44:7<1717::AID-ART299>3.0.CO

[4]

2-C

[5] Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy [J].

Dillman, RO .

CANCER AND METASTASIS REVIEWS, 1999, 18 (04) :465-471

[6] Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis [J].

Edwards, JCW ;

Szczepanski, L ;

Szechinski, J ;

Filipowicz-Sosnowska, A ;

Emery, P ;

Close, DR ;

Stevens, RM ;

Shaw, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2572-2581

[7] Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases [J].

Gottenberg, JE ;

Guillevin, L ;

Lambotte, O ;

Combe, B ;

Allanore, Y ;

Cantagrel, A ;

Larroche, C ;

Soubrier, M ;

Bouillet, L ;

Dougados, M ;

Fain, O ;

Farge, D ;

Kyndt, X ;

Lortholary, O ;

Masson, C ;

Moura, B ;

Remy, P ;

Thomas, T ;

Wendling, D ;

Anaya, JM ;

Sibilia, J ;

Mariette, X .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (06) :913-920

[8]

Grillo-López AJ, 1999, SEMIN ONCOL, V26, P66

[9] Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment [J].

Hellerstedt, B ;

Ahmed, A .

ANNALS OF ONCOLOGY, 2003, 14 (12) :1792-1792

[10] Rituximab-induced serum sickness [J].

Herishanu, Y .

AMERICAN JOURNAL OF HEMATOLOGY, 2002, 70 (04) :329-329

← 1 2 →